Evidence Hub

Metformin for the treatment of polycystic ovary syndrome

Barbieri RL

Obstetrics and gynecology, 2003

84 citations

Abstract

In Brief OBJECTIVE To familiarize obstetrician–gynecologists with the use of metformin for the treatment of polycystic ovary syndrome (PCOS). DATA SOURCES Using OVID, 94 English-language articles published after 1966 indexed with the key words “metformin” and “polycystic ovary syndrome” were identified. METHODS OF STUDY SELECTION Studies were excluded if they did not have a control group, did not use the National Institutes of Health definition of PCOS, did not have a clinical outcome as an end point, and were not in the English language. Reviews were also excluded, leaving 21 articles for inclusion. TABULATION, INTEGRATION, AND RESULTS Three clinical trials reported that for the treatment of anovulatory infertility caused by PCOS, metformin plus clomiphene is more effective than clomiphene alone in inducing ovulation. For the treatment of irregular menses caused by PCOS in women not attempting conception, metformin therapy may restore ovulatory menses in the majority of women. However, most women will require 4–6 months of metformin therapy before they achieve ovulatory menses. In obese women, metformin plus a low-calorie diet may be associated with more weight loss than a low-calorie diet alone. CONCLUSION Polycystic ovary syndrome is a common gynecologic endocrine disorder. Obstetrician–gynecologists should be familiar with the indications and contraindications for the use of metformin in their practice. Metformin is effective in combination with clomiphene for the…

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free